

Ready to start planning your care? Call us at [646-926-0945](tel:646-926-0945) to make an appointment.

×



Memorial Sloan Kettering
Cancer Center

[Make an Appointment](#)

[Back](#)

MEMORIAL HOSPITAL RESEARCH LABORATORIES

[About Memorial Sloan Kettering Cancer Center](#)

The Michael Berger Lab

[About Cancer & Treatment](#)

What can we help you find today?

ABOUT US

[Our mission, vision & core values](#)

[Leadership](#)

[History](#)

[Inclusion & belonging](#)

[Annual report](#)

[Give to MSK](#)

FOR THE MEDIA



Michael F. Berger, PhD

Co-Director, Marie-Josée & Henry R. Kravis Center for Molecular Oncology; Chief Attending, Clinical Computational Diagnostics Service, Department of Pathology and Laboratory Medicine

The focus of the Berger laboratory is to use novel computational and experimental techniques to characterize the spectrum of genetic mutations in human tumors in order to identify biomarkers of cancer progression and drug response.


The identification of molecular drivers of cancer and the development of targeted therapies for these drivers offer hope for better outcomes for patients with cancer. Global efforts to comprehensively

characterize the genomes of all major cancer types continue to reveal new genetic alterations with implications for tumor biology, prognosis, and treatment. Using massively parallel next-generation DNA sequencing, we are developing and applying methods of profiling individual tumor specimenspatient biospecimens for somatic base mutations and other genomicand inherited alterations that may influence response to therapy. Our research falls into two main categories: technology development and biomarker discovery.

[View Lab Overview \(https://www.mskcc.org/research-areas/labs/michael-berger/overview\)](https://www.mskcc.org/research-areas/labs/michael-berger/overview)



Featured News



IN THE LAB

[How Do Inherited Gene Mutations Cause Cancer? A New Database Will](#)

[Help Researchers Find Out](#)

In a new paper, a collaborative team of MSK experts reports how a novel tool will help researchers learn more about the role of inherited hereditary mutations.



FEATURE

[How MSK-ACCESS Blood Test for Cancer was Created](#)

MSK-ACCESS, a blood test that can detect mutations in 129 genes related to cancer, has already helped guide the treatment of more than 2,800 patients at MSK.



FINDING

[Machine Learning May Help Classify Cancers of Unknown Primary](#)

MSK investigators report a new tool that may help them determine the origin of some metastatic tumors, potentially leading to better targeted treatments.

[View All Featured News](#)

Publications Highlights

Genetic Ancestry Correlates with Somatic Differences in a Real-World Clinical Cancer Sequencing Cohort. Arora K, Tran TN, Kemel Y, Mehine M, Liu YL, Nandakumar S, Smith SA, Brannon AR, Ostrovnaya I, Stopsack KH, Razavi P, Safonov A, Rizvi HA, Hellmann MD, Vijai J, Reynolds TC, Fagin JA, Carrot-Zhang J, Offit K, Solit DB, Ladanyi M, Schultz N, Zehir A, Brown CL, Stadler ZK, Chakravarty D, Bandlamudi C, Berger MF. *Cancer Discov.* 2022 Nov 2;12(11):2552-2565. doi: 10.1158/2159-8290.CD-22-0312. PMID: 36048199; PMCID: PMC9633436.

The context-specific role of germline pathogenicity in tumorigenesis. Srinivasan P,

Bandlamudi C, Jonsson P, Kemel Y, Chavan SS, Richards AL, Penson AV, Bielski CM, Fong C, Syed A, Jayakumaran G, Prasad M, Hwee J, Sumer SO, de Bruijn I, Li X, Gao J, Schultz N, Cambria R, Galle J, Mukherjee S, Vijai J, Cadoo KA, Carlo MI, Walsh MF, Mandelker D, Ceyhan-Birsoy O, Shia J, Zehir A, Ladanyi M, Hyman DM, Zhang L, Offit K, Robson ME, Solit DB, Stadler ZK, Berger MF, Taylor BS. *Nat Genet.* 2021 Nov;53(11):1577-1585. doi: 10.1038/s41588-021-00949-1. Epub 2021 Nov 5. PMID: 34741162; PMCID: PMC8957388.

Development of Genome-Derived Tumor Type Prediction to Inform Clinical Cancer Care. Penson A, Camacho N, Zheng Y, Varghese AM, Al-Ahmadie H, Razavi P, Chandarlapaty S, Vallejo CE, Vakiani E, Gilewski T, Rosenberg JE, Shady M, Tsui DWY, Reales DN, Abeshouse A, Syed A, Zehir A, Schultz N, Ladanyi M, Solit DB, Klimstra DS, Hyman DM, Taylor BS, Berger MF. *JAMA Oncol.* 2020 Jan 1;6(1):84-91. doi: 10.1001/jamaoncol.2019.3985. PMID: 31725847; PMCID: PMC6865333.


Tracking tumour evolution in glioma through liquid biopsies of cerebrospinal fluid. Miller AM, Shah RH, Pentsova EI, Pourmaleki M, Briggs S, Distefano N, Zheng Y, Skakodub A, Mehta SA, Campos C, Hsieh WY, Selcuklu SD, Ling L, Meng F, Jing X, Samoila A, Bale TA, Tsui DWY, Grommes C, Viale A, Souweidane MM, Tabar V, Brennan CW, Reiner AS, Rosenblum M, Panageas KS, DeAngelis LM, Young RJ, Berger MF, Mellinghoff IK. *Nature.* 2019 Jan;565(7741):654-658. doi: 10.1038/s41586-019-0882-3. Epub 2019 Jan 23. PMID: 30675060; PMCID: PMC6457907.

Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients. Zehir A, Benayed R, Shah RH, Syed A, Middha S, Kim HR, Srinivasan P, Gao J, Chakravarty D, Devlin SM, Hellmann MD, Barron DA, Schram AM, Hameed M, Dogan S, Ross DS, Hechtman JF, DeLair DF, Yao J, Mandelker DL, Cheng DT, Chandramohan R, Mohanty AS, Ptashkin RN, Jayakumaran G, Prasad M, Syed MH, Rema AB, Liu ZY, Nafa K, Borsu L, Sadowska J, Casanova J, Bacares R, Kiecka IJ, Razumova A, Son JB, Stewart L, Baldi T, Mullaney KA, Al-Ahmadie H, Vakiani E, Abeshouse AA, Penson AV, Jonsson P, Camacho N, Chang MT, Won HH, Gross BE, Kundra R, Heins ZJ, Chen HW, Phillips S, Zhang H, Wang J, Ochoa A, Wills J, Eubank M, Thomas SB, Gardos SM, Reales DN, Galle J, Durany R, Cambria R, Abida W, Cercek A, Feldman DR, Gounder MM, Hakimi AA, Harding JJ, Iyer G, Janjigian YY, Jordan EJ, Kelly CM, Lowery MA, Morris LGT, Omuro AM, Raj N, Razavi P, Shoushtari AN, Shukla N, Soumerai TE, Varghese AM, Yaeger R, Coleman J, Bochner B, Riely GJ, Saltz LB, Scher HI, Sabbatini PJ, Robson ME, Klimstra DS, Taylor BS, Baselga J, Schultz N, Hyman DM, Arcila ME, Solit DB, Ladanyi M,

Berger MF. Nat Med. 2017 Jun;23(6):703-713. doi: 10.1038/nm.4333. Epub 2017 May 8.
Erratum in: Nat Med. 2017 Aug 4;23 (8):1004. PMID: 28481359; PMCID: PMC5461196.

[View All Publications](#)

People



Michael F. Berger, PhD
Co-Director, Marie-Josée & Henry R. Kravis Center for Molecular Oncology; Chief Attending, Clinical Computational Diagnostics Service, Department of Pathology and Laboratory Medicine

- Researcher Michael Berger focuses on massively parallel sequencing of tumor DNA for biomarker discovery and clinical diagnostics.
- PhD, Harvard University

✉ bergem1@mskcc.org
Email Address

☎ [646-888-3386](tel:646-888-3386)
Office Phone

👤 [View physician profile](#)
Physician profile

Members



Chaitanya Bandlamudi
Assistant Lab Member



Kanika Arora
Principal Computational
Biologist

Eric Buehler
Bioinformatics Software
Engineer, CMO Cell-Free DNA
Informatics



Juan Blanco Heredia
Senior Computational Biologist I



Karmelina Charalambous
Computational Biologist, CMO
Cell-Free DNA Informatics



Marissa Granitto
Senior Computational Biologist
II



Caryn Hale
Manager, Computational
Biologist CMO Technology
Innovation Lead

Lab
Alumni

Lab Affiliations

Open Positions

To learn more about available postdoctoral opportunities, please visit our [Career Center](#)

To learn more about compensation and benefits for postdoctoral researchers at MSK, please visit [Resources for Postdocs](#)


Career Opportunities

[Apply](#)

now (<https://www.mskcc.org/research-areas/labs/michael-berger/career-opportunities>)



Vedangi Hambardikar
Scientific Research Lead



Daniel Muldoon
Computational Biologist

Get in Touch


✉ bergerm1@mskcc.org

Lab Head Email

☎ [646-888-3386](tel:646-888-3386)

Office Phone

✕ [_ Twitter Profile](#)



Maria Perry
Senior Computational Biologist I



Sandeep Raj
Instructor

Disclosures

Members of the MSK Community often work with pharmaceutical, device, biotechnology, and life sciences companies, and other organizations outside of MSK, to find safe and effective cancer treatments, to improve patient care, and to educate the health care community. These activities outside of MSK further our mission, provide productive collaborations, and promote the practical application of scientific discoveries.

MSK requires doctors, faculty members, and leaders to report (“disclose”) the relationships and financial interests they have with



Ezra Rosen
Assistant Attending



Ronak Shah
Lead Scientist, CMO Cell-Free
DNA Informatics

external entities. As a commitment to transparency with our community, we make that information available to the public. Not all disclosed interests and relationships present conflicts of interest. MSK reviews all disclosed interests and relationships to assess whether a conflict of interest exists and whether formal COI management is needed.


Michael F. Berger discloses the following relationships and financial interests:



Karthigayini Sivaprakasam
Senior Computational Biologist,
CMO Cell-Free DNA
Informatics



Shalabh Suman
Principal Computational
Biologist



Grittney Tam
Senior Research Assistant,
CMO Technology Innovation

- Professional Services and Activities
- JCO Precision Oncology
Professional Services and Activities
(Uncompensated)
- Journal of Molecular Diagnostics
Professional Services and Activities
(Uncompensated)
- Paige.AI, Inc.
Professional Services and Activities
- SOPHiA GENETICS S.A.
Intellectual Property Rights; Professional
Services and Activities (Uncompensated)

The information published here is a complement to other publicly reported data and is for a specific annual disclosure period. There may be differences between information on this and other public sites as a result of different reporting periods and/or the various ways relationships and

financial interests are categorized by organizations that publish such data.

This page and data include information for a specific MSK annual disclosure period (January 1, 2024 through disclosure submission in spring 2025). This data reflects interests that may or may not still exist. This data is updated annually.

Learn more about MSK’s COI policies [here](#) . For questions regarding MSK’s COI-related policies and procedures, email MSK’s Compliance Office at ecoi@mskcc.org .

[View all disclosures \(https://www.mskcc.org/disclosures\)](https://www.mskcc.org/disclosures)

